medigraphic.com
Sociedad Mexicana de Dermatología y Academia Mexicana de Dermatología.

2016, Número 3

Dermatol Rev Mex 2016; 60 (3)


Actualidades en el tratamiento del prurito crónico

Lagos A, Tirado-Sánchez A, Ponce-Olivera RM

Idioma: Español
Referencias bibliográficas: 114
Paginas: 229-246
Archivo PDF: 557.13 Kb.


RESUMEN

El prurito es el síntoma más importante en diversas enfermedades dermatológicas, como la dermatitis atópica y la psoriasis. La complejidad de la evocación y trasmisión de los impulsos pruriceptivos hacen difícil dilucidar la causa precisa del prurito en cada enfermedad que lo manifiesta. Las formas crónicas del prurito (más de seis semanas) causan deterioro en la calidad de vida de los pacientes. En la actualidad se han dilucidado varios mecanismos de acción y el perfil de seguridad de los tratamientos administrados, como los anestésicos locales, capsaicina, cinc, mentol, alcanfor, inhibidores de la calcineurina, inhibidores de mastocitos, agonistas y antagonistas de los receptores opioides, cannabinoides, talidomida, neurolépticos y algunos inmunosupresores. Asimismo, se han desarrollado nuevos medicamentos específicos a partir de los descubrimientos en las vías pruriceptivas, como los antihistamínicos H4, olopatadina, aprepitant, neurotropina, antagonista del factor de crecimiento nervioso y la semaforina 3A.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Charlesworth EN, Beltrani VS. Pruritic dermatoses: overview of etiology and therapy. Am J Med 2002;113:25-33.

  2. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.

  3. Adame Miranda GJ. Consenso mexicano del tratamiento del prurito. Dermatología Rev Mex 2006;50:148-164.

  4. Weisshaar E, Szepietowski JC, Darsow U, et al. European guideline on chronic pruritus. Acta Derm Venereol 2012;92:563-581.

  5. Weisshaar E, Forster C, Dotzer M, Heyer G. Experimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgesics in atopic eczema. Skin Pharmacol 1997;10:183-190.

  6. Weisshaar E, Heyer G, Forster C, Hornstein OP, Handwerker HO. Antipruritic effect of antihistaminic and local anesthetic topical agents after iontophoretic histamine stimulation. Hautarzt 1996;47:355-360.

  7. Layton AM, Cotterill JA. Notalgia paraesthetica–report of three cases and their treatment. Clin Exp Dermatol 1991;16:197-198.

  8. Szolcsányi J. Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides 2004;38:377-384.

  9. Wallengren J, Håkanson R. Effects of capsaicin, bradykinin and prostaglandin E2 in the human skin. Br J Dermatol 1992;126:111-117.

  10. Lysy J, Sistiery-Ittah M, Israelit Y, et al. Topical capsaicin–a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study. Gut 2003;52:1323-1326.

  11. Wallengren J, Klinker M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol 1995;32:287-289.

  12. Wallengren J. Brachioradial pruritus: a recurrent solar dermopathy. J Am Acad Dermatol 1998;39:803-806.

  13. Hardy J, Uthurriague C, Bibas N, Bon E, et al. Brachioradial pruritus revealing cervicomedullary astrocytoma and treated with 8% capsaicin patches. Ann Dermatol Venereol 2014;141:374-375.

  14. Ellis CN, Berberian B, Sulica VI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Am Acad Dermatol 1993;29:438-442.

  15. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986;15:504-507.

  16. Breneman DL, Cardone JS, Blumsack RF, Lather RM, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992;26:91-94.

  17. Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 1996;72:617- 622.

  18. Boyd K, Shea SM, Patterson JW. The role of capsaicin in dermatology. Prog Drug Res 2014;68:293-306.

  19. Yousefi A, Khani Khoozani Z, Zakerzadeh Forooshani S, Omrani N, et al. Is topical zinc effective in the treatment of melasma? A double-blind randomized comparative study. Dermatol Surg 2014;40:33-37.

  20. Mahajan BB, Dhawan M, Singh R. Herpes genitalis-topical zinc sulfate: an alternative therapeutic and modality. Indian J Sex Transm Dis 2013;34:32-34.

  21. Iraji F, Tagmirriahi N, Gavidnia K. Comparison between the efficacy of 10% zinc sulfate solution with 4% hydroquinone cream on improvement of melasma. Adv Biomed Res 2012;1:39.

  22. Herro E, Jacob SE. Mentha piperita (peppermint). Dermatitis 2010;21:327-329.

  23. Green BG, Schoen KL. Thermal and nociceptive sensations from menthol and their suppression by dynamic contact. Behav Brain Res 2007;176:284-291.

  24. Ma S, G G, Ak VE, Jf D, H H. Menthol derivative WS-12 selectively activates transient receptor potential melastatin-8 (TRPM8) ion channels. Pak J Pharm Sci 2008;21:370-378.

  25. Akhavan Amjadi M, Mojab F, Kamranpour SB. The effect of peppermint oil on symptomatic treatment of pruritus in pregnant women. Iran J Pharm Res 2012;11:1073-1077.

  26. Zuccarini P. Camphor: risks and benefits of a widely used natural product. J Appl Sci Environ Manage 2009;13:69-74.

  27. Macpherson LJ, Hwang SW, Miyamoto T, Dubin AE, et al. More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci 2006;32:335-343.

  28. Sherkheli MA, Benecke H, Doerner JF, et al. Monoterpenoids induce agonist-specific desensitization of transient receptor potential vanilloid-3 (TRPV3) ion channels. J Pharm Pharm Sci 2009;12:116-128.

  29. Ständer S, Luger TA. Antipruritic effects of pimecrolimus and tacrolimus. Hautarzt 2003;54:413-417.

  30. Fleischer AB, Boguniewicz M. An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. J Drugs Dermatol 2010;9:488-498.

  31. Criado PR, Criado RF, Maruta CW, Machado Filho C. Histamine, histamine receptors and antihistamines: new concepts. An Bras Dermatol 2010;85:195-210.

  32. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J 2008;1:145-155.

  33. O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005;18:333-340.

  34. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007;32:34-38.

  35. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Ständer S. Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series. Hautarzt 2009;60:564-568.

  36. Garibyan L, Rheingold CG, Lerner EA. Understanding the pathophysiology of itch. Dermatol Ther 2013;26:84-91.

  37. Glatzer F, Gschwandtner M, Ehling S, et al. Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptor. J Allergy Clin Immunol 2013;132:1358-1367.

  38. Jemima EA, Prema A, Thangam EB. Functional characterization of histamine H4 receptor on human mast cells. Mol Immunol 2014;62:19-28.

  39. Engelhardt H, Smits RA, Leurs R, Haaksma E, de Esch IJ. A new generation of anti-histamines: histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel 2009;12:628-643.

  40. Rossbach K, Wendorff S, Sander K, et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009;18:57- 63.

  41. Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, et al. The histamine H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol 2009;123:619-625.

  42. Grimstad O, Sawanobori Y, Vestergaard C, et al. Antiinterleukin- 31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009;18:35-43.

  43. Smits RA, Leurs R, de Esch IJ. Major advances in the development of histamine H4 receptor ligands. Drug Discov Today 2009;14:745-753. Dermatología Revista mexicana

  44. Liu WL. Histamine H4 receptor antagonists for the treatment of inflammatory disorders. Drug Discov Today 2014;19:1222-1225.

  45. Thurmond RL, Chen B, Dunford PJ, et al. Clinical and preclinical characterization of the histamine H(4) receptor antagonist JNJ-39758979. J Pharmacol Exp Ther 2014;349:176-184.

  46. Kollmeier A, Francke K, Chen B, et al. The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. J Pharmacol Exp Ther 2014;350:181-187.

  47. Francos GC, Kauh YC, Gittlen SD, et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991;30:884-889.

  48. Sharma AD. Oral ketotifen and topical antibiotic therapy in the management of pruritus in prurigo nodularis: a randomized, controlled, single-blind, parallel study. Indian J Dermatol 2013;58:355-359.

  49. Vessal G, Sagheb MM, Shilian S, Jafari P, Samani SM. Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrol Dial Transplant 2010;25:1541-1547.

  50. Rosner MH. Cromolyn sodium: a potential therapy for uremic pruritus? Hemodial Int 2006;10:189-192.

  51. Leven A, Naysmith A, Pickens S, Pottage A. Sodium cromoglycate and Hodgkin's pruritus. Br Med J 1977;2:896.

  52. Czarnetzki BM, Brechtel B, Braun-Falco O, et al. Topical tiacrilast, a potent mast cell degranulation inhibitor, does not improve adult atopic eczema. Dermatology 1993;187:112- 114.

  53. Haider SA. Treatment of atopic eczema in children: clinical trial of 10% sodium cromoglycate ointment. Br Med J 1977;1:1570-1572.

  54. Stainer R, Matthews S, Arshad SH, et al. Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial. Br J Dermatol 2005;152:334-341.

  55. Feily A, Dormanesh B, Ghorbani AR, et al. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients. Int J Clin Pharmacol Ther 2012;50:510-513.

  56. Vieira Dos Santos R, Magerl M, Martus P, et al. Topical sodium cromoglicate relieves allergen-and histamine-induced dermal pruritus. Br J Dermatol 2010;162:674-676.

  57. Fjellner B, Hägermark O. Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and morphine. Arch Dermatol Res 1982;274:29-37.

  58. Phan NQ, Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges 2010;8:88-91.

  59. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012;92:502-507.

  60. Mettang T, Kremer AE. Uremic pruritus. Kidney Int 2015;87:685-691.

  61. Mettang M, Weisshaar E. Pruritus: control of itch in patients undergoing dialysis. Skin Therapy Lett 2010;15:1-5.

  62. Böttcher B, Wildt L. Treatment of refractory vulvovaginal pruritus with naltrexone, a specific opiate antagonist. Eur J Obstet Gynecol Reprod Biol 2014;174:115-116.

  63. Nakao K, Mochizuki H. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today 2009;45:323-329.

  64. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res. 2003;52:238-245.

  65. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008;22:73-82.

  66. Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010;11:1673-1682.

  67. Kanitakis J. Brachioradial pruritus: report of a new case responding to gabapentin. Eur J Dermatol 2006;16:311- 312.

  68. Loosemore MP, Bordeaux JS, Bernhard JD. Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy. J Eur Acad Dermatol Venereol 2007;21:1440-1441.

  69. Maciel AA, Cunha PR, Laraia IO, Trevisan F. Efficacy of gabapentin in the improvement of pruritus and quality of life of patients with notalgia paresthetica. An Bras Dermatol 2014;89:570-575.

  70. Rayner H, Baharani J, Smith S, Suresh V, Dasgupta I. Uraemic pruritus: relief of itching by gabapentin and pregabalin. Nephron Clin Pract 2012;122:75-79.

  71. Solak Y, Biyik Z, Atalay H, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton) 2012;17:710-717.

  72. Imai K, Kishimoto M, Tsujimoto T, et al. Successful treatment of chronic intractable itching using oral pregabalin in a patient with diabetes and systemic prurigo nodularis: a case report of an iliopsoas muscle abscess. Intern Med 2013;52:2629-2633.

  73. Ahuja RB, Gupta GK. A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of post-burn pruritus. Burns 2013;39:24-29.

  74. Ordi-Ros J, Cosiglio FJ. Current therapeutic indications of thalidomide and lenalidomide. Med Clin (Barc) 2014;142:360-364.

  75. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-1060.

  76. Gonçalves F. Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease. Am J Hosp Palliat Care 2010;27:486-487.

  77. Orlando A, Renna S, Cottone M. Prurigo nodularis of Hyde treated with low-dose thalidomide. Eur Rev Med Pharmacol Sci 2009;13:141-145.

  78. Alfadley A, Al-Hawsawi K, Thestrup-Pedersen K, Al-Aboud K. Treatment of prurigo nodularis with thalidomide: a case report and review of the literature. Int J Dermatol 2003;42:372-375.

  79. Hon KL, Ching GK, Leung TF, Chow CM, et al. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat 2009;20:141-145.

  80. Calikoglu E, Anadolu R. Management of generalized pruritus in dominant dystrophic epidermolysis bullosa using low-dose oral cyclosporin. Acta Derm Venereol 2002;82:380-382.

  81. Fusaro M, Munaretto G, Spinello M, Gallieni M. Regression of uraemic pruritus by cyclosporin treatment in a haemodialysis patient. Nephrol Dial Transplant 2004;19:1338- 1339.

  82. Panahi Y, Taherzadeh ES, Davoudi SM, Sahebkar A, Ranjbar R. Investigation of serum substance P status in patients with chronic pruritic skin lesions due to sulfur mustard: a cross-sectional study. Cutan Ocul Toxicol 2013;32:4-8.

  83. Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges 2014;12:557-559.

  84. Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol 2012;66:14- 15.

  85. Palacios Zabalza I, López de Torre Querejazu A, Santos Ibañez A. Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma. Farm Hosp 2014;38:145-147.

  86. Jiménez Gallo D, Albarrán Planelles C, Linares Barrios M, Fernández Anguita MJ, et al. Treatment of pruritus in earlystage hypopigmented mycosis fungoides with aprepitant. Dermatol Ther 2014;27:178-182.

  87. Borja-Consigliere HA, López-Pestaña A, Vidal-Manceñido MJ, Tuneu-Valls A. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-Cell lymphoma. Actas Dermosifiliogr 2014;105:716-718.

  88. Ally MS, Gamba CS, Peng DH, Tang JY. The use of aprepitant in brachioradial pruritus. JAMA Dermatol 2013;149:627- 628.

  89. Murota H, El-latif MA, Tamura T, Amano T, Katayama I. Olopatadine hydrochloride improves dermatitis score and inhibits scratch behavior in NC/Nga mice. Int Arch Allergy Immunol 2010;153:121-132.

  90. Ohsawa Y, Hirasawa N. The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy 2012;67:1014-1022.

  91. Murota H, El-latif MA, Tamura T, Katayama I. Olopatadine hydrochloride decreases tissue interleukin-31 levels in an atopic dermatitis mouse model. Acta Derm Venereol 2014;94:78-79.

  92. Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol 2014;41:205-212.

  93. Yoshii H, Suehiro S, Watanabe K, Yanagihara Y. Immunopharmacological actions of an extract isolated from inflamed skin of rabbits inoculated with vaccinia virus (neurotropin); enhancing effect on delayed type hypersensitivity response through the induction of Lyt-1+2- T cells. Int J Immunopharmacol 1987;9:443-451.

  94. Yago H, Fujita Y, Kaku H, et al. Study on pruritus in hemodialysis patients and the antipruritic effect of neurotropin: plasma levels of C3a, C5a, bradykinin and lipid peroxides. Nihon Jinzo Gakkai Shi 1989;31:1061-1067.

  95. Taneda K, Tominaga M, Tengara S, Ogawa H, Takamori K. Neurotropin inhibits both capsaicin-induced substance P release and nerve growth factor-induced neurite outgrowth in cultured rat dorsal root ganglion neurones. Clin Exp Dermatol 2010;35:73-77.

  96. Kamo A, Tominaga M, Taneda K, Ogawa H, Takamori K. Neurotropin inhibits the increase in intraepidermal nerve density in the acetone-treated dry-skin mouse model. Clin Exp Dermatol 2013;38:665-668.

  97. Papoiu AD, Wang H, Nattkemper L, et al. A study of serum concentrations and dermal levels of NGF in atopic dermatitis and healthy subjects. Neuropeptides 2011;45:417- 422.

  98. Takano N, Sakurai T, Kurachi M. Effects of anti-nerve growth factor antibody on symptoms in the NC/Nga mouse, an atopic dermatitis model. J Pharmacol Sci 2005;99:277-286.

  99. Takano N, Sakurai T, Ohashi Y, Kurachi M. Effects of highaffinity nerve growth factor receptor inhibitors on symptoms in the NC/Nga mouse atopic dermatitis model. Br J Dermatol 2007;156:241-246.

  100. Taniguchi M, Matsuzaki S, Tohyama M. P75 plays a key role in the induction of the sprouting of sensory nerve fibers in inflamed skin. J Invest Dermatol 2007;127:2062-2065.

  101. Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 1993;75:1389-1399.

  102. Fiore R, Püschel AW. The function of semaphorins during nervous system development. Front Biosci 2003;8:484-499.

  103. Fujisawa H. Discovery of semaphorin receptors, neuropilin and plexin, and their functions in neural development. J Neurobiol 2004;59:24-33.

  104. Sharma A, Verhaagen J, Harvey AR. Receptor complexes for each of the Class 3 Semaphorins. Front Cell Neurosci 2012;6:28.

  105. Tang XQ, Tanelian DL, Smith GM. Semaphorin3A inhibits nerve growth factor-induced sprouting of nociceptive afferents in adult rat spinal cord. J Neurosci 2004;24:819-827.

  106. Tominaga M, Ogawa H, Takamori K. Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis. Br J Dermatol 2008;158:842-844.

  107. Chang SE, Han SS, Jung HJ, Choi JH. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 2007;156:1272-1277.

  108. Kurschat P, Bielenberg D, Rossignol-Tallandier M, Stahl A, Klagsbrun M. Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration. J Biol Chem 2006;281:2721-2729.

  109. Fukamachi S, Bito T, Shiraishi N, et al. Modulation of semaphorin 3A expression by calcium concentration and histamine in human keratinocytes and fibroblasts. J Dermatol Sci 2011;61:118-123.

  110. Yamaguchi J, Nakamura F, Aihara M, et al. Semaphorin3A alleviates skin lesions and scratching behavior in NC/ Nga mice, an atopic dermatitis model. J Invest Dermatol 2008;128:2842-2849.

  111. Kou K, Nakamura F, Aihara M, et al. Decreased expression of semaphorin-3A, a neurite-collapsing factor, is associated with itch in psoriatic skin. Acta Derm Venereol 2012;92:521-528.

  112. Takada S, Kou K, Nagashima Y, Ikezawa Z, Aihara M. Aberrant epidermal expression of semaphorin 3A and nerve growth factor in prurigo nodularis. J Dermatol 2013;40:404- 406.

  113. Negi O, Tominaga M, Tengara S, et al. Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC/Nga mice with atopic dermatitis. J Dermatol Sci 2012;66:37-43.

  114. Romeo PH, Lemarchandel V, Tordjman R. Neuropilin-1 in the immune system. Adv Exp Med Biol 2002;515:49-54.




2020     |     www.medigraphic.com